NCT/Study#
NCT03397706 /
VT3996-201
A Phase 1b/2 Open-Label, Dose Escalation And Expansion Study Of Orally Administered Vrx-3996 And Valganciclovir In Subjects With Epstein-Barr Virus-Associated Lymphoid Malignancies
DISEASE GROUP:
Lymphoma
current phase:
Phase I/II
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information:
Call 201-518-3587
